IP Library › Patent Application 12714235
Patent Application
App. No. 12/714,235

METHODS OF TREATING NEOPLASTIC, AUTOIMMUNE AND INFLAMMATORY DISEASES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/714,235
Abstract

Methods of treating cancer and autoimmune and inflammatory diseases are provided.

Claims (17)

1 . A method of treating a patient having acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), comprising administering an unconjugated humanized M195 antibody to the patient at a dose of 1.5 to about 12 mg/kg body weight, whereby progression of the AML or MDS is inhibited.

2 . The method of claim 1 , wherein the antibody is administered at weekly intervals for a period of about one to three months.

3 . The method of claim 2 , further comprising administering the antibody at biweekly intervals for a period of one to six months.

4 - 10 . (canceled)

11 . The method of claim 1 , whereby at least one symptom of AML associated cachexia is reduced.

12 . (canceled)

13 . The method of claim 1 , wherein the humanized M195 antibody decreases the number of involved non-malignant effector cells, and/or decreases the levels of one or more inflammatory cytokines, chemokines or growth factors, in the patient.

14 - 17 . (canceled)

18 . The method of claim 1 , wherein the patient is at least 60 years of age.

19 - 27 . (canceled)

28 . A method of treating acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) in a patient, or of preventing or delaying recurrence of AML or MDS in a patient in remission, comprising administering an unconjugated humanized M195 antibody to the patient at a dose of 550-650 mg regardless of body weight.

29 . The method of claim 28 , wherein the antibody is administered at weekly intervals for a period of about one to three months.

30 . The method of claim 28 , whereby at least one symptom of AML associated cachexia is reduced.

31 . The method of claim 28 , wherein the patient is at least 60 years of age.

32 . The method of claim 28 , wherein the antibody is administered at a dose of about 600 mg.

33 . The method of claim 32 , wherein the antibody is administered at weekly intervals for a period of about one to three months.

34 . The method of claim 32 , wherein the patient is at least 60 years of age.